Clinical Trials
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with ...
February 23, 2026 | News
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...
February 23, 2026 | News
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...
February 23, 2026 | News
-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...
February 20, 2026 | News
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...
February 20, 2026 | News
Mammotome, a Danaher company, announces the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System, the industry's first system designed t...
February 19, 2026 | News
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...
February 19, 2026 | News
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...
February 18, 2026 | News
- Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical too...
February 17, 2026 | News
Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...
February 16, 2026 | News
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnolog...
February 16, 2026 | News
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005...
February 16, 2026 | News
Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") announced that they have entere...
February 13, 2026 | News
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) applicat...
February 13, 2026 | News
Most Read
Bio Jobs
News